Monocyte MicroRNA Expression in Active Systemic Juvenile Idiopathic Arthritis Implicates MicroRNA-125a-5p in Polarized Monocyte Phenotypes

Arthritis and Rheumatology

Volumn 68, Issue 9, 2016, Pages 2300-2313

  Schulert, Grant S ^a   Fall, Ndate ^a   Harley, John B ^a   Shen, Nan ^a   Lovell, Daniel J ^a   Thornton, Sherry ^a   Grom, Alexei A ^a  

^a CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; MICRORNA; MICRORNA 125A 5P; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; ARTICLE; CELL FUNCTION; CELL POLARITY; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOKINE PRODUCTION; FEMALE; GENE EXPRESSION; GENE OVEREXPRESSION; GENETIC ASSOCIATION; HUMAN; HUMAN CELL; IMMUNE DYSREGULATION; IN VITRO STUDY; MACROPHAGE; MALE; MICROARRAY ANALYSIS; MOLECULAR PATHOLOGY; MONOCYTE; PATHOGENESIS; PHENOTYPE; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS; YOUNG ADULT;

EID: 84983516273     PISSN: 23265191     EISSN: 23265205     Source Type: Journal    
DOI: 10.1002/art.39694     Document Type: Article

References (66)

1. Petty RE, Southwood TR, Manners P, Baum J, Glass DN, Goldenberg J, et al. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol 2004;31:390–2.
2. Ravelli A, Grom AA, Behrens EM, Cron RQ. Macrophage activation syndrome as part of systemic juvenile idiopathic arthritis: diagnosis, genetics, pathophysiology and treatment. Genes Immun 2012;13:289–98.
3. Mellins ED, Macaubas C, Grom AA. Pathogenesis of systemic juvenile idiopathic arthritis: some answers, more questions. Nat Rev Rheumatol 2011;7:416–26.
4. Fall N, Barnes M, Thornton S, Luyrink L, Olson J, Ilowite NT, et al. Gene expression profiling of peripheral blood from patients with untreated new-onset systemic juvenile idiopathic arthritis reveals molecular heterogeneity that may predict macrophage activation syndrome. Arthritis Rheum 2007;56:3793–804.
5. Pascual V, Allantaz F, Arce E, Punaro M, Banchereau J. Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade. J Exp Med 2005;201:1479–86.
6. Allantaz F, Chaussabel D, Stichweh D, Bennett L, Allman W, Mejias A, et al. Blood leukocyte microarrays to diagnose systemic onset juvenile idiopathic arthritis and follow the response to IL-1 blockade. J Exp Med 2007;204:2131–44.
7. Ogilvie EM, Khan A, Hubank M, Kellam P, Woo P. Specific gene expression profiles in systemic juvenile idiopathic arthritis. Arthritis Rheum 2007;56:1954–65.
8. Macaubas C, Nguyen K, Deshpande C, Phillips C, Peck A, Lee T, et al. Distribution of circulating cells in systemic juvenile idiopathic arthritis across disease activity states. Clin Immunol 2010;134:206–16.
9. De Benedetti F, Massa M, Robbioni P, Ravelli A, Burgio GR, Martini A. Correlation of serum interleukin-6 levels with joint involvement and thrombocytosis in systemic juvenile rheumatoid arthritis. Arthritis Rheum 1991;34:1158–63.
10. Ling XB, Park JL, Carroll T, Nguyen KD, Lau K, Macaubas C, et al. Plasma profiles in active systemic juvenile idiopathic arthritis: biomarkers and biological implications. Proteomics 2010;10:4415–30.
11. Martinez FO, Gordon S. The M1 and M2 paradigm of macrophage activation: time for reassessment. F1000Prime Rep 2014;6:13.
12. Martinez FO, Sica A, Mantovani A, Locati M. Macrophage activation and polarization. Front Biosci 2008;13:453–61.
13. Gordon S. Alternative activation of macrophages. Nat Rev Immunol 2003;3:23–35.
14. Fleming BD, Mosser DM. Regulatory macrophages: setting the threshold for therapy. Eur J Immunol 2011;41:2498–502.
15. Edwards JP, Zhang X, Frauwirth KA, Mosser DM. Biochemical and functional characterization of three activated macrophage populations. J Leukoc Biol 2006;80:1298–307.
16. Sironi M. Differential regulation of chemokine production by Fcγ receptor engagement in human monocytes: association of CCL1 with a distinct form of M2 monocyte activation (M2b, Type 2). J Leukoc Biol 2006;80:342–9.
17. Zizzo G, Hilliard BA, Monestier M, Cohen PL. Efficient clearance of early apoptotic cells by human macrophages requires M2c polarization and MerTK induction. J Immunol 2012;189:3508–20.
18. Lang R, Patel D, Morris JJ, Rutschman RL, Murray PJ. Shaping gene expression in activated and resting primary macrophages by IL-10. J Immunol 2002;169:2253–63.
19. Williams L, Jarai G, Smith A, Finan P. IL-10 expression profiling in human monocytes. J Leukoc Biol 2002;72:800–9.
20. Zhou D, Huang C, Lin Z, Zhan S, Kong L, Fang C, et al. Macrophage polarization and function with emphasis on the evolving roles of coordinated regulation of cellular signaling pathways. Cell Signal 2014;26:192–7.
21. Graff JW, Dickson AM, Clay G, McCaffrey AP, Wilson ME. Identifying functional microRNAs in macrophages with polarized phenotypes. J Biol Chem 2012;287:21816–25.
22. Luo X, Ranade K, Talker R, Jallal B, Shen N, Yao Y. MicroRNA-mediated regulation of innate immune response in rheumatic diseases. Arthritis Res Ther 2013;15:210.
23. Lucherini OM, Obici L, Ferracin M, Fulci V, McDermott MF, Merlini G, et al. First report of circulating microRNAs in tumour necrosis factor receptor-associated periodic syndrome (TRAPS). PLoS One 2013;8:e73443.
24. Kamiya Y, Kawada JI, Kawano Y, Torii Y, Kawabe S, Iwata N, et al. Serum microRNAs as potential biomarkers of juvenile idiopathic arthritis. Clin Rheumatol 2015;34:1705–12.
25. Ma X, Wu F, Xin L, Su G, He F, Yang Y, et al. Differential plasma microRNAs expression in juvenile idiopathic arthritis. Mod Rheumatol 2016;26:224–32.
26. Jiang K, Hu Z, Chen Y, Jarvis JN. Deep sequencing reveals differential small RNA expression in serum exosomes of children with juvenile idiopathic arthritis [abstract]. Arthritis Rheumatol 2014;66 Suppl S3:S230.
27. Shimizu M, Yachie A. Compensated inflammation in systemic juvenile idiopathic arthritis: role of alternatively activated macrophages. Cytokine 2012;60:226–32.
28. Maeno N, Takei S, Imanaka H, Yamamoto K, Kuriwaki K, Kawano Y, et al. Increased interleukin-18 expression in bone marrow of a patient with systemic juvenile idiopathic arthritis and unrecognized macrophage-activation syndrome. Arthritis Rheum 2004;50:1935–8.
29. Macaubas C, Nguyen KD, Peck A, Buckingham J, Deshpande C, Wong E, et al. Alternative activation in systemic juvenile idiopathic arthritis monocytes. Clin Immunol 2012;142:362–72.
30. Cobos Jiménez V, Bradley EJ, Willemsen AM, van Kampen AH, Baas F, Kootstra NA. Next-generation sequencing of microRNAs uncovers expression signatures in polarized macrophages. Physiol Genomics 2014;46:91–103.
31. Zhang Y, Zhang M, Zhong M, Suo Q, Lv K. Expression profiles of miRNAs in polarized macrophages. Int J Mol Med 2013;31:797–802.
32. Banerjee S, Cui H, Xie N, Tan Z, Yang S, Icyuz M, et al. miR-125a-5p regulates differential activation of macrophages and inflammation. J Biol Chem 2013;288:35428–36.
33. DeWitt EM, Kimura Y, Beukelman T, Nigrovic PA, Onel K, Prahalad S, et al, on behalf of the Juvenile Idiopathic Arthritis Disease-Specific Research Committee of the Childhood Arthritis And Rheumatology Research Alliance. Consensus treatment plans for new-onset systemic juvenile idiopathic arthritis. Arthritis Care Res (Hoboken) 2012;64:1001–10.
34. Wallace CA, Giannini EH, Huang B, Itert L, Ruperto N, for the Childhood Arthritis and Rheumatology Research Alliance (CARRA), the Pediatric Rheumatology Collaborative Study Group (PRCSG), and the Paediatric Rheumatology International Trials Organisation (PRINTO). American College of Rheumatology provisional criteria for defining clinical inactive disease in select categories of juvenile idiopathic arthritis. Arthritis Care Res (Hoboken) 2011;63:929–36.
35. Gantier MP, Tong S, Behlke MA, Xu D, Phipps S, Foster PS, et al. TLR7 is involved in sequence-specific sensing of single-stranded RNAs in human macrophages. J Immunol 2008;180:2117–24.
36. Sikora KA, Fall N, Thornton S, Grom AA. The limited role of interferon-γ in systemic juvenile idiopathic arthritis cannot be explained by cellular hyporesponsiveness. Arthritis Rheum 2012;64:3799–808.
37. Murata K, Yoshitomi H, Tanida S, Ishikawa M, Nishitani K, Ito H, et al. Plasma and synovial fluid microRNAs as potential biomarkers of rheumatoid arthritis and osteoarthritis. Arthritis Res Ther 2010;12:R86.
38. Stanczyk J, Pedrioli DM, Brentano F, Sanchez-Pernaute O, Kolling C, Gay RE, et al. Altered expression of microRNA in synovial fibroblasts and synovial tissue in rheumatoid arthritis. Arthritis Rheum 2008;58:1001–9.
39. Niimoto T, Nakasa T, Ishikawa M, Okuhara A, Izumi B, Deie M, et al. MicroRNA-146a expresses in interleukin-17 producing T cells in rheumatoid arthritis patients. BMC Musculoskelet Disord 2010;11:209.
40. Pauley KM, Satoh M, Chan AL, Bubb MR, Reeves WH, Chan EK. Upregulated miR-146a expression in peripheral blood mononuclear cells from rheumatoid arthritis patients. Arthritis Res Ther 2008;10:R101.
41. Philippe L, Alsaleh G, Pichot A, Ostermann E, Zuber G, Frisch B, et al. miR-20a regulates ASK1 expression and TLR4-dependent cytokine release in rheumatoid fibroblast-like synoviocytes. Ann Rheum Dis 2013;72:1071–9.
42. Mogilyansky E, Rigoutsos I. The miR-17/92 cluster: a comprehensive update on its genomics, genetics, functions and increasingly important and numerous roles in health and disease. Cell Death Differ 2013;20:1603–14.
43. Naqvi AR, Fordham JB, Nares S. miR-24, miR-30b, and miR-142-3p regulate phagocytosis in myeloid inflammatory cells. J Immunol 2015;194:1916–27.
44. Iliopoulos D, Hirsch HA, Struhl K. An epigenetic switch involving NF-κB, Lin28, Let-7 microRNA, and IL6 links inflammation to cell transformation. Cell 2009;139:693–706.
45. Wei Y, Nazari-Jahantigh M, Chan L, Zhu M, Heyll K, Corbalán-Campos J, et al. The microRNA-342-5p fosters inflammatory macrophage activation through an Akt1- and microRNA-155-dependent pathway during atherosclerosis. Circulation 2013;127:1609–19.
46. Bazzoni F, Rossato M, Fabbri M, Gaudiosi D, Mirolo M, Mori L, et al. Induction and regulatory function of miR-9 in human monocytes and neutrophils exposed to proinflammatory signals. Proc Natl Acad Sci U S A 2009;106:5282–7.
47. Wendlandt EB, Graff JW, Gioannini TL, McCaffrey AP, Wilson ME. The role of microRNAs miR-200b and miR-200c in TLR4 signaling and NF-κB activation. Innate Immun 2012;18:846–55.
48. Liu Y, Chen Q, Song Y, Lai L, Wang J, Yu H, et al. MicroRNA-98 negatively regulates IL-10 production and endotoxin tolerance in macrophages after LPS stimulation. FEBS Lett 2011;585:1963–8.
49. Prokopec KE, Berntson L, Öman A, Kleinau S. Up regulated complement and fc receptors in juvenile idiopathic arthritis and correlation with disease phenotype. J Clin Immunol 2012;32:540–50.
50. Rodriguez A, Vigorito E, Clare S, Warren MV, Couttet P, Soond DR, et al. Requirement of bic/microRNA-155 for normal immune function. Science 2007;316:608–11.
51. Trenkmann M, Brock M, Gay RE, Michel BA, Gay S, Huber LC. Tumor necrosis factor α–induced microRNA-18a activates rheumatoid arthritis synovial fibroblasts through a feedback loop in NF-κB signaling. Arthritis Rheum 2013;65:916–27.
52. Kolenda T, Przybyła W, Teresiak A, Mackiewicz A, Lamperska KM. The mystery of let-7d: a small RNA with great power. Contemp Oncol (Pozn) 2014;18:293–301.
53. Zhou R, Li X, Hu G, Gong AY, Drescher KM, Chen XM. miR-16 targets transcriptional corepressor SMRT and modulates NF-κB-regulated transactivation of interleukin-8 gene. PLoS One 2012;7:e30772.
54. Bandyopadhyay S, Lane T, Venugopal R, Parthasarathy PT, Cho Y, Galam L, et al. MicroRNA-133a-1 regulates inflammasome activation through uncoupling protein-2. Biochem Biophys Res Commun 2013;439:407–12.
55. Grom AA, Ilowite NT, Pascual V, Brunner HI, Martini A, Lovell D, et al. Rate and clinical presentation of macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis treated with canakinumab. Arthritis Rheumatol 2016;68:218–28.
56. Sumegi J, Nestheide S, Aronow B, Fletcher D, Keddache M, Villanueva J, et al. MicroRNA activation signature in patients with hemophagocytic lymphohistiocytosis and reversibility with disease-specific therapy. J Allergy Clin Immunol 2016;137:309–12.
57. Zhao X, Tang Y, Qu B, Cui H, Wang S, Wang L, et al. MicroRNA-125a contributes to elevated inflammatory chemokine RANTES levels via targeting KLF13 in systemic lupus erythematosus. Arthritis Rheum 2010;62:3425–35.
58. Murata K, Furu M, Yoshitomi H, Ishikawa M, Shibuya H, Hashimoto M, et al. Comprehensive microRNA analysis identifies miR-24 and miR-125a-5p as plasma biomarkers for rheumatoid arthritis. PLoS One 2013;8:e69118.
59. Pan W, Zhu S, Dai D, Liu Z, Li D, Li B, et al. miR-125a targets effector programs to stabilize Treg-mediated immune homeostasis. Nat Commun 2015;6:7096.
60. Nigrovic PA. Is there a window of opportunity for treatment of systemic juvenile idiopathic arthritis? [review]. Arthritis Rheumatol 2014;66:1405–13.
61. Eigsti RL, Sudan B, Wilson ME, Graff JW. Regulation of activation-associated microRNA accumulation rates during monocyte-to-macrophage differentiation. J Biol Chem 2014;289:28433–47.
62. De Benedetti F, Brunner HI, Ruperto N, Kenwright A, Wright S, Calvo I, et al. Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis. N Engl J Med 2012;367:2385–95.
63. Bleesing J, Prada A, Siegel DM, Villanueva J, Olson J, Ilowite NT, et al. The diagnostic significance of soluble CD163 and soluble interleukin-2 receptor α-chain in macrophage activation syndrome and untreated new-onset systemic juvenile idiopathic arthritis. Arthritis Rheum 2007;56:965–971.
64. Behrens EM, Beukelman T, Paessler M, Cron RQ. Occult macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis. J Rheumatol 2007;34:1133–8.
65. Chaudhuri AA, So AY, Sinha N, Gibson WS, Taganov KD, O'Connell RM, et al. MicroRNA-125b potentiates macrophage activation. J Immunol 2011;187:5062–8.
66. El Chartouni C, Schwarzfischer L, Rehli M. Interleukin-4 induced interferon regulatory factor (Irf) 4 participates in the regulation of alternative macrophage priming. Immunobiology 2010;215:821–5.